XML 49 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets and Royalty Agreement (Details) (USD $)
3 Months Ended 3 Months Ended 0 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Mar. 31, 2014
Licenses
Dec. 31, 2013
Licenses
Jan. 29, 2007
Licenses
Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.
Mar. 31, 2014
Licenses
Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.
Jan. 05, 2011
Licenses
Surgical Biologics, LLC
Mar. 31, 2014
Patents & Know How
Dec. 31, 2013
Patents & Know How
Mar. 31, 2014
Patents & Know How
Surgical Biologics, LLC
Jan. 05, 2011
Patents & Know How
Surgical Biologics, LLC
Mar. 31, 2014
Customer & Supplier Relationships
Dec. 31, 2013
Customer & Supplier Relationships
Jan. 05, 2011
Customer & Supplier Relationships
Surgical Biologics, LLC
Mar. 31, 2014
Tradenames & Trademarks
Dec. 31, 2013
Tradenames & Trademarks
Jan. 05, 2011
Tradenames & Trademarks
Surgical Biologics, LLC
Mar. 31, 2014
In Process Research & Development
Dec. 31, 2013
In Process Research & Development
Jan. 05, 2011
In Process Research & Development
Surgical Biologics, LLC
Mar. 31, 2014
Patents in Process
Dec. 31, 2013
Patents in Process
Finite-Lived Intangible Assets [Line Items]                                              
Weighted Average Amortization Lives       10 years [1],[2]         14 years [1]       14 years [1]                    
Gross Carrying Value       $ 1,009,000 [1],[2] $ 1,009,000 [1],[2]     $ 13,000 $ 7,855,825 [1] $ 7,798,910 [1]   $ 7,690,000 $ 3,761,000 [1] $ 3,761,000 [1] $ 3,761,000                
Weighted Average Amortization Lives, Indefinite Lived                               indefinite [1]     indefinite [1]     indefinite [3]  
Gross Carrying Value, Indefinite Lived                               1,008,000 [1] 1,008,000 [1] 1,008,000 25,000 [1] 25,000 [1] 25,000 691,018 [3] 579,987 [3]
Total 14,349,843   14,181,897                                        
Less Accumulated amortization and impairment charges (3,234,655)   (3,003,324)                                        
Net 11,115,188   11,178,573                                        
Acquisition price           996,000                                  
Maximum time of approval           30 days                                  
Contingent payments to licensor             200,000                                
Contingent royalty to be paid to licensor (in hundredths)             3.00%                                
Annual royalty payment           50,000                                  
Net book value 10,107,188           284,000                                
Finite-Lived Intangible Assets, Costs                     56,915                        
Amortization of intangible assets 231,331 262,596                                          
Estimated future amortization expense [Abstract]                                              
2014 695,462 [4]                                            
2015 927,283                                            
2016 927,283                                            
2017 837,650                                            
2018 827,683                                            
Thereafter 5,891,827                                            
Net book value $ 10,107,188           $ 284,000                                
[1] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2014 an additional $56,915 of costs associated with patents granted during the period were capitalized and included in Patents & Know- How subject to amortization.
[2] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2014, this license had a remaining net book value of approximately $284,000
[3] Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
[4] Estimated amortization expense for the year ending December 31, 2014 includes only amortization to be recorded after March 31, 2014.